San Francisco Sentry Investment Group’s Acadia Pharmaceuticals ACAD Stock Holding History

San Francisco Sentry Investment Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,325	Closed	-$36K	–	891
2018 Q2	$36K	Sell	2,325 -3,652	-61%	-$65.1K	0.01%	417
2018 Q1	$134K	Buy	5,977 +250	+4%	+$6.92K	0.04%	323
2017 Q4	$172K	Buy	5,727 +1,300	+29%	+$41.6K	0.05%	281
2017 Q3	$167K	Sell	4,427 -52	-1%	-$1.69K	0.06%	270
2017 Q2	$125K	Buy	+4,479	New	+$133K	0.04%	279
2014 Q4	–	Sell	-2,790	Closed	-$69K	–	159
2014 Q3	$69K	Buy	2,790 +1,040	+59%	+$24.3K	0.03%	264
2014 Q2	$40K	Buy	1,750 +1,450	+483%	+$30.3K	0.02%	345
2014 Q1	$7K	Hold	300	–	–	﹤0.01%	562
2013 Q4	$7K	Buy	+300	New	+$7.08K	﹤0.01%	534

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

San Francisco Sentry Investment Group's ACAD Position: Q3 2018 in Review

San Francisco Sentry Investment Group sold out of Acadia Pharmaceuticals (ACAD) in Q3 2018, closing a stake of 2,325 shares — an estimated $36K sold.

San Francisco Sentry Investment Group first reported a position in ACAD in Q4 2013 and held it in 9 quarters. The position peaked at $172K in Q4 2017. 184 funds tracked by Wall St. Rank hold ACAD as of Q3 2018.

San Francisco Sentry Investment Group reported no remaining Acadia Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
San Francisco Sentry Investment Group sold 2,325 Acadia Pharmaceuticals shares in Q3 2018, an estimated $36K.
San Francisco Sentry Investment Group first reported a position in Acadia Pharmaceuticals in Q4 2013 and held it in 9 quarters.
San Francisco Sentry Investment Group's Acadia Pharmaceuticals position peaked at $172K in Q4 2017.
184 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2018.

Based on San Francisco Sentry Investment Group's 13F filing for Q3 2018, filed 9 Nov 2018.